Elranatamab: First Approval

2023/11/01 by Sohita Dhillon · 22 citations
Medicine · #CAR-T cell therapy research #Multiple Myeloma Research and Treatments #Monoclonal and Polyclonal Antibodies Research

paper · doi:10.1007/s40265-023-01954-w

Cited by

• Structure and function of therapeutic antibodies approved by the US FDA in 2023
• Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engager. [europepmc]
• A pivotal decade for bispecific antibodies? [europepmc]
• A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023. [europepmc]
• Structure and function of therapeutic antibodies approved by the US FDA in 2023. [europepmc]
• Multiple myeloma: signaling pathways and targeted therapy. [europepmc]
• Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment. [europepmc]
• Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023. [europepmc]
• Targeting GPRC5D for multiple myeloma therapy. [europepmc]
• Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies. [europepmc]
• Polypharmacology: new drugs in 2023-2024. [europepmc]
• Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma. [europepmc]
• The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma. [europepmc]
• Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials. [europepmc]
• Reprogramming cancer immunity with next-generation combination therapies. [europepmc]
• Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs. [europepmc]
• Advances in the clinical application of bispecific antibodies in cancer therapy. [europepmc]
• Next-generation T cell engagers in oncology: Pharmacologic evolution from bispecific to trispecific antibodies. [europepmc]
• TPP-45142-an Anti-HER2 T-cell Engager-Designed for Selective HER2-Low Cancer Immunotherapy. [europepmc]
• The making of multispecific immunoglobulins - a clinical perspective. [europepmc]
• Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions. [europepmc]
• Discovery of co-stimulatory anti-CD28 VHHs for developing cancer immune therapeutic anti-tumor/CD3/CD28 trispecific T cell engager. [europepmc]